福瑞股份：医疗黑科技带来新变革 从伦敦马拉松看FibroScan全球战略

Group 1 - The core message emphasizes the importance of early screening for liver diseases, highlighted by the participation of Camille, an executive from the French subsidiary of Furuya Co., in the London Marathon [1] - Furuya Co.'s FibroScan technology is recognized as the "gold standard" for liver disease diagnosis, facilitating non-invasive liver fibrosis detection and contributing to the Healthy China strategy [1] - The World Health Organization (WHO) reports that approximately 800,000 people die from liver cancer annually, with China accounting for nearly half of these cases, underscoring the urgency of addressing liver health [1] Group 2 - FibroScan technology marks a shift from subjective doctor-dependent assessments to AI-driven precision in liver disease detection, identifying liver fat changes as low as 5% [2] - The introduction of FibroScan in leading domestic health institutions like Aikang Guobin enhances efficiency by over 80%, providing quick assessments of liver health in just 3-5 minutes [2] - Furuya Co. is actively involved in the EU LIVERAIM project, the largest liver disease clinical trial to date, aiming to develop a personalized early diagnosis screening platform using AI, with over 100,000 participants [2]